Read below for Selected Safety Information.
They couldn't be more excited to learn about OPZELURA® (ruxolitinib) cream, 1.5% and how it could help relieve symptoms of mild to moderate eczema.
This video is intended for informational use only, and is not designed to replace the medical advice of your healthcare provider. OPZELURA is a prescription medicine used on the skin (topical) for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised adults and children 12 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended. The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended. It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis or nonsegmental vitiligo.
Selected Safety Information
OPZELURA can cause serious side effects including serious infections, increased risk of death due to any reason, cancer and immune system problems, increased risk of major cardiovascular events, and blood clots.
OPZELURA can lower your ability to fight infections, including TB or hepatitis B or C. Serious lung infections, skin cancer, blood clots, and low blood cell counts occurred with OPZELURA. Before starting OPZELURA, tell your doctor if you have an infection, are being treated for one, have TB or have been in close contact with someone with TB; have or had hepatitis B or C. Your doctor should check for infections before and during treatment. Tell your doctor if you had blood clots in your legs or lungs. OPZELURA may cause low platelet, low red and white blood cell counts.
In people taking JAK inhibitors, serious infections, increased risk of death, lymphoma, other cancers, and major cardiovascular events have occurred. OPZELURA is a topical JAK inhibitor. People 50 and older with at least 1 heart disease risk factor have an increased risk of heart attack, stroke, blood clots, and death when taking JAK inhibitors by mouth. The most common side effects of OPZELURA in people treated for atopic dermatitis include: common cold (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).
Call your doctor for medical advice about side effects. To learn more about these and other risks, please read the Important Safety Information at www.opzelura.com/atopic-dermatitis/#ISI.
Please see the Full Prescribing Information and Medication Guide at www.opzelura.com/opzelura-prescribing-information which includes a more complete discussion of the risks associated with OPZELURA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463.
Sponsored by Incyte Corporation. OPZELURA is a registered trademark of Incyte.
© 2024, Incyte. MAT-OPZ-02353 05/24